Barclays raised the firm’s price target on Novo Nordisk to DKK 1,200 from DKK 1,075 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk raises sales and operating profit outlook for 2023
- Novo Nordisk upgraded to Outperform from Neutral at Credit Suisse
- Novo Nordisk, Aspect Biosystems announce bioprinted tissue partnership
- Novo Nordisk price target raised to DKK 1,152 from DKK 1,081 at Guggenheim
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports